Association of lead exposure with survival in amyotrophic lateral sclerosis

Environmental Health Perspectives

Volumn 116, Issue 7, 2008, Pages 943-947

  Kamel, Freya ^a   Umbach, David M ^b   Stallone, Lilian ^c   Richards, Marie ^d   Hu, Howard ^e   Sandler, Dale P ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^d WESTAT   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Amyotrophic lateral sclerosis; Lead; Prognosis; Survival

Indexed keywords

LEAD;

ADULT; AGE DISTRIBUTION; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BONE LEVEL; CASE CONTROL STUDY; CAUSE OF DEATH; CIGARETTE SMOKING; CONTROLLED STUDY; DEATH CERTIFICATE; DISEASE COURSE; ENVIRONMENTAL EXPOSURE; FEMALE; GENDER BIAS; HUMAN; INFORMATION RETRIEVAL; LEAD BLOOD LEVEL; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; ONSET AGE; PATELLA; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; SURVIVAL TIME; TIBIA;

ADULT; AGE FACTORS; AGED; AMYOTROPHIC LATERAL SCLEROSIS; BONE AND BONES; CASE-CONTROL STUDIES; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; LEAD; MALE; MIDDLE AGED; SEX FACTORS; SMOKING; SURVIVAL ANALYSIS;

EID: 46749092091     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.11193     Document Type: Article

References (32)

1. Armon C. 2003. An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis. Neuroepidemiology 22:217-228.
2. Barbeito AG, Guelfi N, Varga MR, Pehar M, Beckman J, Barbeito L, et al. 2005. Chronic low-level lead exposure increases survival of G93A SOD-1 transgenic mice [Abstract]. In: Amyotrophic Lateral Sclerosis: Beyond the Motor Neuron. Available: http://iibce.edu.uy/ALSmeeting/abstract.htm [accessed 14 April 2008].
3. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al. 2006. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312:1389-1392.
4. Brody DJ, Pirkle JL, Kramer RA, Flegal KM, Matte TD, Gunter EW, et al. 1994. Blood lead levels in the US population. Phase 1 of the Third National Health and Nutrition Examination Survey (NHANES III, 1988 to 1991). JAMA 272:277-283.
5. Brooks BR. 1994. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 124:96-107.
6. Campbell AMG, Williams ER, Barltrop D. 1970. Motor neuron disease and exposure to lead. J Neurol Neurosurg Psychiatry 33:220-226.
7. Chancellor AM, Swingler RJ, Fraser H, Clarke JA, Warlow CP. 1993. Utility of Scottish morbidity and mortality data for epidemiological studies of motor neuron disease. J Epidemiol Community Health 47:116-120.
8. Chio A, Magnani C, Oddenino E, Tolardo G, Schiffer D. 1992. Accuracy of death certificate diagnosis of amyotrophic lateral sclerosis. J Epidemiol Community Health 46:517-518.
9. Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, et al. 2002. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 59:99-103.
10. Czaplinski A, Yen AA, Simpson EP, Appel SH. 2006. Predictability of disease progression in amyotrophic lateral sclerosis. Muscle Nerve 34:702-708.
11. Dean G, Quigley M, Goldacre M. 1994. Motor neuron disease in a defined English population - estimates of incidence and mortality. J Neurol Neurosurg Psychiatry 57:450-454.
12. del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G. 2003. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 60:813-819.
13. Glymour MM. 2007. Invited commentary: when bad genes look good - APOE*E4, cognitive decline, and diagnostic thresholds. Am J Epidemiol 165:1239-1246.
14. Guiloff RJ, Goonetilleke A. 1995. Natural history of amyotrophic lateral sclerosis. Observations with the Charing Cross Amyotrophic Lateral Sclerosis Rating Scales. Adv Neurol 68:185-198.
15. Gunnarsson LG, Palm R. 1984. Motor neuron disease and heavy manual labor: an epidemiologic survey of Varmland County, Sweden. Neuroepidemiology 3:195-206.
16. Hoffman PM, Brody JA. 1971. The reliability of death certificate reporting for amyotrophic lateral sclerosis. J Chronic Dis 24:5-8.
17. Hu H, Payton M, Korrick S, Aro A, Sparrow D, Weiss ST, et al. 1996. Determinants of bone and blood lead levels among community-exposed middle-aged to elderly men. Am J Epidemioi 144:749-759.
18. Hu H, Shih R, Rothenberg S, Schwartz BS. 2007. The epidemiology of lead toxicity in adults: measuring dose and consideration of other methodologic issues. Environ Health Perspect 115:455-462.
19. Kamel F, Umbach DM, Hu H, Munsat TL, Shefner JM, Taylor JA, et al. 2005. Lead exposure as a risk factor for amyotrophic lateral sclerosis. Neurodegen Dis 2:195-201.
20. Kamel F, Umbach D, Lehman T, Park L, Munsat T, Shefner J, et al. 2003. Amyotrophic lateral sclerosis, lead, and genetic susceptibility: polymorphisms in the δ-amino-levulinic acid dehydratase and vitamin D receptor genes. Environ Health Perspect 111:1335-1339.
21. Kamel F, Umbach DM, Munsat TL, Shefner JM, Hu H, Sandler DP. 2002. Lead exposure and amyotrophic lateral sclerosis. Epidemiology 13:311-319.
22. Kamel F, Umbach DM, Munsat TL, Shefner JM, Sandler DP. 1999. Association of cigarette smoking with amyotrophic lateral sclerosis. Neuroepidemiology 18:194-202.
23. Korrick SA, Schwartz J, Tsaih SW, Hunter DJ, Aro A, Rosner B, et al. 2002. Correlates of bone and blood lead levels among middle-aged and elderly women. Am J Epidemiol 156:335-343.
24. Kunst CB. 2004. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet 75:933-947.
25. McGuire V, Longstreth W Jr, Nelson L, Koepsell T, Checkoway H, Morgan M, et al. 1997. Occupational exposures and amyotrophic lateral sclerosis: a population-based case-control study. Am J Epidemiol 145:1076-1088.
26. Millul A, Beghi E, Logroscino G, Micheli A, Vitelli E, Zardi A. 2005. Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology 25:114-119.
27. Mitchell JD, Borasio GD. 2007. Amyotrophic lateral sclerosis. Lancet 369:2031-2041.
28. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. 2005. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord 6:37-44.
29. Ragonese P, Filippini G, Salemia G, Beghi E, Citterio A, D'Alessandro R, et al. 2004. Accuracy of death certificates for amyotrophic lateral sclerosis varies significantly from north to south of Italy: implications for mortality studies. Neuroepidemiology 23:73-77.
30. Savitz DA, Checkoway H, Loomis DP. 1998. Magnetic field exposure and neurodegenerative disease mortality among electric utility workers. Epidemiology 9:398-404.
31. Turabelidze G, Zhu BP, Schootman M, Malone JL, Horowitz S, Weidinger J, et al. 2008. An epidemiologic investigation of amyotrophic lateral sclerosis in Jefferson County, Missouri, 1998-2002. Neurotoxicology 29:81-86.
32. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. 2002. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 3:15-21.